The present invention relates to bacteriophage therapy. More particularly, the present invention relates to novel bacteriophages having a high specificity against Staphylococcus aureus strains, their manufacture, components thereof, compositions comprising the same and the uses thereof in phage therapy and as companion diagnostic.

The present invention relates to bacteriophage therapy. More particularly, the present invention relates to novel bacteriophages having a high specificity against Staphylococcus aureus strains, their manufacture, components thereof, compositions comprising the same and the uses thereof in phage therapy and as companion diagnostic.

The present invention provides methods for the prevention, control, disruption and treatment of bacterial biofilms with lysin, particularly lysin having capability to kill Staphlococcal bacteria, including drug resistant Staphylococcus aureus, particularly the lysin PlySs2. The invention also provides compositions and methods for use in treatment or modulation of bacterial biofilm(s) and biofilm formation.

The present invention provides methods for the prevention, control, disruption and treatment of bacterial biofilms with lysin, particularly lysin having capability to kill Staphlococcal bacteria, including drug resistant Staphylococcus aureus, particularly the lysin PlySs2. The invention also provides compositions and methods for use in treatment or modulation of bacterial biofilm(s) and biofilm formation.

The invention provides combinations of bacteriophages for use in reducing and preventing growth of Salmonella enterica and Escherichia coli.

The invention provides combinations of bacteriophages for use in reducing and preventing growth of Salmonella enterica and Escherichia coli.

The invention provides combinations of bacteriophages for use in reducing and preventing growth of Salmonella enterica and Escherichia coli.

Described herein are compositions for treating or preventing a viral infection comprising bacteriophages that bind to the virus and block or inhibit viral entry into a host cell. Bacteriophage libraries may be screened to identify bacteriophages that bind to a virus of interest, and the identified bacteriophages may be used to treat or prevent an infection caused by the virus of interest. Also described herein are methods of treating or preventing a viral infection by administering a bacteriophage composition to a subject in vivo or to a surface in vitro. The bacteriophages in the composition may bind to the virus and inhibit viral entry into a host cell, thereby reducing the infectivity of the virus. Reducing the infectivity of the virus may treat or prevent the viral infection.

Described herein are compositions for treating or preventing a viral infection comprising bacteriophages that bind to the virus and block or inhibit viral entry into a host cell. Bacteriophage libraries may be screened to identify bacteriophages that bind to a virus of interest, and the identified bacteriophages may be used to treat or prevent an infection caused by the virus of interest. Also described herein are methods of treating or preventing a viral infection by administering a bacteriophage composition to a subject in vivo or to a surface in vitro. The bacteriophages in the composition may bind to the virus and inhibit viral entry into a host cell, thereby reducing the infectivity of the virus. Reducing the infectivity of the virus may treat or prevent the viral infection.

The present invention relates to Podoviridae bacteriophage Pse-AEP-4 (accession number: KCTC 13166BP) isolated from nature, the Podoviridae bacteriophage Pse-AEP-4 having the capability to specifically kill Pseudomonas aeruginosa and having a genome represented by SEQ ID NO: 1, and a method for preventing or treating diseases induced by Pseudomonas aeruginosa by using a composition containing the Podoviridae bacteriophage Pse-AEP-4 as an active ingredient.